Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney A Appell

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Emerging Drugs|March 1, 2006
The emergence of new drugs for overactive bladderRebecca J McCrery, Phillip P Smith, Rodney A Appell
Urology|February 19, 2008
Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinenceEric A Hurtado, Rebecca J McCrery, Rodney A Appell
Current Urology Reports|November 16, 2004
A case for botulinum toxin-A in idiopathic bladder overactivityChristopher P Smith, George T Somogyi, Michael B Chancellor, et al.
Neurourology and Urodynamics|December 13, 2002
Baseline abdominal pressure and valsalva leak point pressures-correlation with clinical and urodynamic dataShahar Madjar, Matteo Balzarro, Rodney A Appell, et al.
Clinical Pharmacokinetics|November 9, 2004
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutyninGayatri Sathyan, Roger R Dmochowski, Rodney A Appell, et al.
Mayo Clinic Proceedings|August 26, 2003
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjectsRodney A Appell, Michael B Chancellor, R Howard Zobrist, et al.
BJU International|October 18, 2005
Bladder-health diaries: an assessment of 3-day vs 7-day entriesRoger R Dmochowski, Steven W Sanders, Rodney A Appell, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|September 4, 2009
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndromePeter K Sand, Roger R Dmochowski, Norman R Zinner, et al.
BJU International|May 12, 2006
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturiaVictor W Nitti, Roger Dmochowski, Rodney A Appell, et al.
International Urogynecology Journal|March 27, 2010
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence statusMarc R Toglia, Donald R Ostergard, Rodney A Appell, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Emerging Drugs|March 1, 2006
The emergence of new drugs for overactive bladderRebecca J McCrery, Phillip P Smith, Rodney A Appell
Urology|February 19, 2008
Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinenceEric A Hurtado, Rebecca J McCrery, Rodney A Appell
Current Urology Reports|November 16, 2004
A case for botulinum toxin-A in idiopathic bladder overactivityChristopher P Smith, George T Somogyi, Michael B Chancellor, et al.
Neurourology and Urodynamics|December 13, 2002
Baseline abdominal pressure and valsalva leak point pressures-correlation with clinical and urodynamic dataShahar Madjar, Matteo Balzarro, Rodney A Appell, et al.
Clinical Pharmacokinetics|November 9, 2004
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutyninGayatri Sathyan, Roger R Dmochowski, Rodney A Appell, et al.
Mayo Clinic Proceedings|August 26, 2003
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjectsRodney A Appell, Michael B Chancellor, R Howard Zobrist, et al.
BJU International|October 18, 2005
Bladder-health diaries: an assessment of 3-day vs 7-day entriesRoger R Dmochowski, Steven W Sanders, Rodney A Appell, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|September 4, 2009
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndromePeter K Sand, Roger R Dmochowski, Norman R Zinner, et al.
BJU International|May 12, 2006
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturiaVictor W Nitti, Roger Dmochowski, Rodney A Appell, et al.
International Urogynecology Journal|March 27, 2010
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence statusMarc R Toglia, Donald R Ostergard, Rodney A Appell, et al.
Pageof 6